Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading

Journal of Diabetes Research
Hector Garcia-AlcalaD Ziegler

Abstract

Effective treatment of diabetic sensorimotor polyneuropathy remains a challenge. To assess the efficacy and safety of α-lipoic acid (ALA) over 20 weeks, we conducted a multicenter randomized withdrawal open-label study, in which 45 patients with type 2 diabetes and symptomatic polyneuropathy were initially treated with ALA (600 mg tid) for 4 weeks (phase 1). Subsequently, responders were randomized to receive ALA (600 mg qd; n = 16) or to ALA withdrawal (n = 17) for 16 weeks (phase 2). During phase 1, the Total Symptom Score (TSS) decreased from 8.9 ± 1.8 points to 3.46 ± 2.0 points. During phase 2, TSS improved from 3.7 ± 1.9 points to 2.5 ± 2.5 points in the ALA treated group (p < 0.05) and remained unchanged in the ALA withdrawal group. The use of analgesic rescue medication was higher in the ALA withdrawal group than ALA treated group (p < 0.05). In conclusion, in type 2 diabetic patients with symptomatic polyneuropathy who responded to initial 4-week high-dose (600 mg tid) administration of ALA, subsequent treatment with ALA (600 mg qd) over 16 weeks improved neuropathic symptoms, whereas ALA withdrawal was associated with a higher use of rescue analgesic drugs. This trial is registered with ClinicalTrials.gov Identifier: ...Continue Reading

Associated Clinical Trials

May 12, 2015·Hector Garcia-Alcala, Hector Garcia-Alcala

References

Feb 3, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·K J RuhnauD Ziegler
Feb 12, 2000·Diabetes Research and Clinical Practice·B S GalerM P Jensen
Feb 27, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·D ZieglerP A Low
Nov 4, 2005·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Joel RaskinJoachim F Wernicke
Aug 23, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·C DaousiI A MacFarlane
Feb 23, 2007·The Clinical Journal of Pain·Ariel BergerGerry Oster
Sep 24, 2011·Therapeutics and Clinical Risk Management·Courtney E McIlduff, Seward B Rutkove
Feb 6, 2013·Diabetes/metabolism Research and Reviews·Andrew J M BoultonDan Ziegler
Jun 26, 2013·British Journal of Anaesthesia·R A MooreP J Wiffen
Sep 23, 2014·Journal of Diabetes and Its Complications·Dan Ziegler, Vivian Fonseca
Nov 11, 2014·Expert Opinion on Pharmacotherapy·Nikolaos Papanas, Dan Ziegler
Nov 21, 2014·Handbook of Clinical Neurology·Dan ZieglerJonathan E Shaw
Jan 13, 2015·Lancet Neurology·Nanna B FinnerupMark Wallace

❮ Previous
Next ❯

Citations

Jun 20, 2016·Current Diabetes Reports·Rick T Dobrowsky
Jul 6, 2020·Clinical and Experimental Pharmacology & Physiology·Thekkuttuparambil A Ajith
Apr 11, 2018·Oxidative Medicine and Cellular Longevity·Nicholas E BuglakEdward S M Bahnson
Aug 14, 2019·Biomolecules·Bahare SalehiJavad Sharifi-Rad
May 28, 2021·Curēus·Arsalan ZaheerMuhammad Waqas Tahir
Aug 28, 2021·Current Diabetes Reports·Tina Okdahl, Christina Brock

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02439879

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.